Search results
Showing 646 to 660 of 748 results for mental health
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
explanatory notes(if applicable) Care and treatment for physical health conditions (recommendations 1.10.18 and 1.10.19) The...
circumstances. This is based on the definition of social care in section 65 of the Health andSocial Care Act 2012.At present access to...
More people are benefitting from NICE-recommended statins to reduce heart attacks and strokes
Around 5.3 million people in England were given a NICE-recommended statin or ezetimibe by their GP to help reduce their cholesterol during 2023/24, the largest number on record and almost 900,000 more than in 2022/23.
Heart valve disease presenting in adults: investigation and management (NG208)
This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)
Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.
Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)
This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .
This guideline covers identifying and managing otitis media with effusion (OME), also known as ‘glue ear’, in children younger than 12 years. It aims to improve hearing and quality of life in children with OME.
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)
Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms in myelofibrosis in adults.
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)
This guideline covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS (COPD–OSAHS overlap syndrome) in people over 16. It aims to improve recognition, investigation and treatment of these related conditions.
Methods for the development of NICE public health guidance (third edition) (PMG4)
Methods for the development of NICE public health guidance (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection and scoping the guidance
- 3 Determining the evidence for review and consideration
- 4 Identifying the evidence
- 5 Reviewing the scientific evidence
- 6 Incorporating health economics
- 7 Developing recommendations
- Appendix A Conceptual framework for the work of the Centre for Public Health Excellence (CPHE)
Palforzia for treating peanut allergy in children and young people (TA769)
Evidence-based recommendations on Palforzia for treating peanut allergy in children and young people.